| DC49069 |
MAX-40279 hemiadipate
Featured
|
MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032). |
|
| DC49081 |
RET-IN-5 |
RET-IN-5 is a potent RET (rearranged during transfection) inhibitor with an IC50s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18). |
|
| DC49088 |
EGFR-IN-26 |
EGFR-IN-26 is a EGFR inhibitor extracted from patent WO2019162323A1 compound I-028. EGFR-IN-26 can be used for the research of cancer. |
|
| DC49104 |
RET-IN-6 |
RET-IN-6 is a potent RET (rearranged during transfection) inhibitor with an IC50 of 4.57 nM (CN113461670A, compound 321). |
|
| DC49109 |
EGFR-IN-24 |
EGFR-IN-24, a potent EGFR inhibitor, shows inhibition against EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S), respectively. |
|
| DC49127 |
Oritinib |
Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively. |
|
| DC49160 |
EGFR-IN-25 |
EGFR-IN-25 is a potent EGFR inhibitor with IC50s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively. |
|
| DC49163 |
EGFR-IN-27 |
EGFR-IN-27 is a potent EGFR inhibitor with IC50s of <50 nM for EGFR Del, L858R, Del/T790M, L858R/T790M, Del/T790M/C797S, and L858R/T790M/C797S, respectively (WO2021249324A1, compound 511). |
|
| DC49172 |
EGFR-IN-21 |
EGFR-IN-21 is a potent EGFR inhibtior with an IC50 of 0.38 nM. EGFR-IN-21 has antitumor activity. |
|
| DC49173 |
EGFR-IN-23 |
EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC50 of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8). |
|
| DC49188 |
EGFR-IN-22 |
EGFR-IN-22 is a potent EGFR inhibitor with IC50s of 4.91 nM and 0.54 nM for wild type EGFR and EGFRL858R/T790M/C797S, respectively (CN112538072A, compound 243). |
|
| DC49189 |
Con B-1 |
ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells. |
|
| DC49413 |
Insulin glargine |
Insulin glargine is a long-acting insulin analog. Insulin glargine can be used for the diabetes mellitus. |
|
| DC50089 |
BLK-IN-1 |
BLK-IN-1 (compound 1) is a selective and covalent inhibitor of B-Lymphoid tyrosine kinase (BLK) and BTK, with IC50s of 18.8 nM and 20.5 nM, respectively. BLK-IN-1 can be used for the research of cancer. |
|
| DC50094 |
BTK-IN-7 |
BTK-IN-7 is a potent and selective inhibitor of BTK (IC50=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels(ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity. |
|
| DC50095 |
EGFR-IN-34 |
EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12). |
|
| DC50097 |
(E)-AG 556 |
(E)-AG 556 is a highly selective EGFR inhibitor and also blocks LPS-induced TNF-α production. |
|
| DC50100 |
EGFR-IN-29 |
EGFR-IN-29 is a potent EGFR inhibitor, example J-022, extracted from Patent WO2021160087. |
|
| DC50101 |
HER2-IN-5 |
HER2-IN-5 is a potent and orally active HER-2 inhibitor, example 10, extracted from patent WO2021164697. |
|
| DC50102 |
EGFR-IN-32 |
EGFR-IN-32 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-32 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185297A1, compound 2). |
|
| DC50103 |
EGFR-IN-31 |
EGFR-IN-31 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-31 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185298A1, compound 2). |
|
| DC50104 |
EGFR-IN-39 |
EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2). |
|
| DC50105 |
EGFR-IN-38 |
EGFR-IN-38 is a potent inhibitor of EGFR. EGFR-IN-38 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4). |
|
| DC50106 |
EGFR-IN-37 |
EGFR-IN-37 is a potent inhibitor of EGFR. EGFR-IN-37 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7). |
|
| DC50107 |
EGFR-IN-36 |
EGFR-IN-36 is a potent EGFR inhibitor with IC50s of 19.09 nM, 120.01 nM, 2.35 nM for EGFR (WT), HER2 (WT), HER2 (A775_G776insYVMA), respectively. EGFR-IN-36 has potential for wild and/or mutant EGFR and/or HER2 kinase mediated tumors research. |
|
| DC50108 |
EGFR-IN-35 |
EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11). |
|
| DC50109 |
EGFR-IN-33 |
EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13). |
|
| DC50110 |
EGFR-IN-30 |
EGFR-IN-30 is a potent EGFR inhibitor with IC50s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research. |
|
| DC50111 |
EGFR-IN-28 |
EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity. |
|
| DC50112 |
Methyl 2,5-dihydroxycinnamate |
Methyl 2,5-dihydroxycinnamate is an erbstatin analog and a stable, potent inhibitor of EGFR kinase activity. |
|
